Guidelines for diagnosis and management of bronchial asthma: Joint ICS/NCCP (I) recommendations

Lung India

Volumn 32, Issue 7, 2015, Pages S3-S42

  Agarwal, Ritesh ^a   Dhooria, Sahajal ^a   Aggarwal, Ashutosh Nath ^a   Maturu, Venkata N ^a   Sehgal, Inderpaul S ^a   Muthu, Valliappan ^a   Prasad, Kuruswamy T ^a   Yenge, Lakshmikant B ^a   Singh, Navneet ^a   Behera, Digambar ^a   Jindal, Surinder K ^a   Gupta, Dheeraj ^a   Balamugesh, Thanagakunam ^a   Bhalla, Ashish ^a   Chaudhry, Dhruva ^a   Chhabra, Sunil K ^a   Chokhani, Ramesh ^a   Chopra, Vishal ^a   Dadhwal, Devendra S ^a   D'Souza, George ^a   Garg, Mandeep ^a   Gaur, Shailendra N ^a   Gopal, Bharat ^a   Ghoshal, Aloke G ^a   Guleria, Randeep ^a   Gupta, Krishna B ^a   Haldar, Indranil ^a   Jain, Sanjay ^a   Jain, Nirmal K ^a   Jain, Vikram K ^a   Janmeja, Ashok K ^a   Kant, Surya ^a   Kashyap, Surender ^a   Khilnani, Gopi C ^a   Kishan, Jai ^a   Kumar, Raj ^a   Koul, Parvaiz A ^a   Mahashur, Ashok ^a   Mandal, Amit K ^a   Malhotra, Samir ^a   Mohammed, Sabir ^a   Mohapatra, Prasanta R ^a   Patel, Dharmesh ^a   Prasad, Rajendra ^a   Ray, Pallab ^a   Samaria, Jai K ^a   Singh, Potsangbam Sarat ^a   Sawhney, Honey ^a   Shafiq, Nusrat ^a   Sharma, Navneet ^a   Sidhu, Updesh Pal S ^a   Singla, Rupak ^a   Suri, Jagdish C ^a   Talwar, Deepak ^a   Varma, Subhash ^a   more..

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHACHOLINE; TIOTROPIUM BROMIDE;

ADD ON THERAPY; AIRWAY OBSTRUCTION; ALLERGY; ASTHMA; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DRUG MEGADOSE; DYSPNEA; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; MONOTHERAPY; PEAK EXPIRATORY FLOW; PRACTICE GUIDELINE; RESPIRATORY AIRFLOW; REVIEW; SPIROMETRY; THORAX RADIOGRAPHY; TREATMENT PLANNING; WHEEZING;

EID: 84927728485     PISSN: 09702113     EISSN: 0974598X     Source Type: Journal    
DOI: 10.4103/0970-2113.154517     Document Type: Review

References (453)

1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.; GRADE Working Group. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
2. Guyatt GH, Rennie D, Meade MO, Cook DJ. Users Guide to the Medical Literature: A Manual for Evidence-Based Clinical Practice. 2nd ed. New York: McGraw Hill; 2008.
3. Ciba Guest Symposium. Terminology, definitions and classification of chronic pulmonary emphysema and related conditions. Thorax 1959;14:286-99.
4. National Heart, Lung and Blood Institute. Guidelines for the diagnosis and management of asthma. National Asthma Education and Prevention Program. Available from: http://www.nhlbi.nih.gov/files/docs/guidelines/ asthgdln.pdf. [Last accessed on 2014 Mar 5].
5. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Vancouver (WA): Global Initiative for Asthma (GINA); 2012. p. 110.
6. Levy ML, Thomas M, Small I, Pearce L, Pinnock H, Stephenson P. Summary of the 2008 BTS/SIGN British Guideline on the management of asthma. Prim Care Respir J 2009;18 Suppl 1:S1-16.
7. Jindal SK, Gupta D, Aggarwal AN, Agarwal R. World Health Organization; Government of India. Guidelines for management of asthma at primary and secondary levels of health care in India (2005). Indian J Chest Dis Allied Sci 2005;47:309-43.
8. Masoli M, Fabian D, Holt S, Beasley R; Global Initiative for Asthma (GINA) Program. The global burden of asthma: Executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469-78.
9. To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global asthma prevalence in adults: Findings from the cross-sectional world health survey. BMC Public Health 2012;12:204.
10. The Global Asthma Report. International Union against Tuberculosis and Lung Disease, Paris, 2011. Available from: http://www. globalasthmanetwork.org/publications/Global-Asthma-Report-2011. pdf. [Last accessed on 2014 Mar 5].
11. Chhabra SK, Gupta CK, Chhabra P, Rajpal S. Risk factors for development of bronchial asthma in children in Delhi. Ann Allergy Asthma Immunol 1999;83:385-90.
12. Gupta D, Aggarwal AN, Kumar R, Jindal SK. Prevalence of bronchial asthma and association with environmental tobacco smoke exposure in adolescent school children in Chandigarh, north India. J Asthma 2001;38:501-7.
13. Chakravarthy S, Singh RB, Swaminathan S, Venkatesan P. Prevalence of asthma in urban and rural children in Tamil Nadu. Natl Med J India 2002;15:260-3.
14. Awasthi S, Kalra E, Roy S, Awasthi S. Prevalence and risk factors of asthma and wheeze in school-going children in Lucknow, north India. Indian Pediatr 2004;41:1205-10.
15. Sharma SK, Banga A. Prevalence and risk factors for wheezing in children from rural areas of north India. Allergy Asthma Proc 2007;28:647-53.
16. Kumar R, Nagar JK, Raj N, Kumar P, Kushwah AS, Meena M, et al. Impact of domestic air pollution from cooking fuel on respiratory allergies in children in India. Asian Pac J Allergy Immunol 2008;26:213-22.
17. Behl RK, Kashyap S, Sarkar M. Prevalence of bronchial asthma in school children of 6-13 years of age in Shimla city. Indian J Chest Dis Allied Sci 2010;52:145-8.
18. Chowgule RV, Shetye VM, Parmar JR, Bhosale AM, Khandagale MR, Phalnitkar SV, et al. Prevalence of respiratory symptoms, bronchial hyperreactivity and asthma in a megacity. Results of the European community respiratory health survey in Mumbai (Bombay). Am J Respir Crit Care Med 1998;158:547-54.
19. Jindal SK, Gupta D, Aggarwal AN, Jindal RC, Singh V. Study of the prevalence of asthma in adults in North India using a standardized field questionnaire. J Asthma 2000;37:345-51.
20. Gaur SN, Gupta K, Rajpal S, Singh AB, Rohatgi A. Prevalence of bronchial asthma and allergic rhinitis among urban and rural adult population of Delhi. Indian J Allergy Asthma Immunol 2006;20:90-7.
21. Gupta PR, Mangal DK. Prevalence and risk factors for bronchial asthma in adults in Jaipur district of Rajasthan (India). Lung India 2006;23:53-8.
22. Parasuramalu BG, Huliraj N, Rudraprasad BM, Prashanth Kumar SP, Ramesh Masthi NR; Gangaboraiah. Prevalence of bronchial asthma and its association with smoking habits among adult population in rural area. Indian J Public Health 2010;54:165-8.
23. Gaur SN, Kumar R, Sinha R. Prevalence of bronchial asthma in petrol pump workers of Delhi. Indian J Occup Environ Med 2003;7:13-6.
24. Gaur SN, Gupta K, Rajpal S, Agarwal N, Singh AB, Rohatgi A. Prevalence of bronchial asthma and allergic rhinitis among industrial workers in Delhi, India. Intern Med J Thai 2005;21:13-8.
25. Agrawal S, Pearce N, Ebrahim S. Prevalence and risk factors for self-reported asthma in an adult Indian population: A cross-sectional survey. Int J Tuberc Lung Dis 2013;17:275-82.
26. Aggarwal AN, Chaudhry K, Chhabra SK, DSouza GA, Gupta D, Jindal SK, et al.; Asthma Epidemiology Study Group. Prevalence and risk factors for bronchial asthma in Indian adults: A multicentre study. Indian J Chest Dis Allied Sci 2006;48:13-22.
27. Jindal SK, Aggarwal AN, Gupta D, Agarwal R, Kumar R, Kaur T, et al. Indian study on epidemiology of asthma, respiratory symptoms and chronic bronchitis in adults (INSEARCH). Int J Tuberc Lung Dis 2012;16:1270-7.
28. Jindal SK. Burden of asthma in India. Int J Tuberc Lung Dis 2013;17:145.
29. Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med 2013;369:448-57.
30. The European Lung White Book. The first comprehensive survey on respiratory health in Europe, 2003. Available from: http://www. erswhitebook.org/chapters/the-economic-burden-of-lung-disease/. [Last accessed on 2014 March 05].
31. Barnett SB, Nurmagambetov TA. Costs of asthma in the United States: 2002-2007. J Allergy Clin Immunol 2011;127:145-52.
32. Murthy KJR, Sastry JG. Economic burden of asthma. Back-ground papers; Burden of disease in India. Available from: http://www.who. int/macrohealth/action/NCMH-Burden%20of%20disease-%2829%20 Sep%202005%29.pdf. [Last accessed on 2014 Mar 5].
33. WHO Fact sheet No. 307, 2013, Updated November 2013, Geneva, Switzerland. Available from: http://www.who.int/mediacentre/factsheets/ fs307/en/. [Last accessed on 2014 Mar 5].
34. Vercelli D. Gene-environment interactions in asthma and allergy: The end of the beginning?. Curr Opin Allergy Clin Immunol 2010;10:145-8.
35. Dijk FN, de Jongste JC, Postma DS, Koppelman GH. Genetics of onset of asthma. Curr Opin Allergy Clin Immunol 2013;13:193-202.
36. Birbian N, Singh J, Jindal SK. High risk association of IL-1 receptor antagonist (IL-1RN) VNTR polymorphism with asthma in a north Indian population: A pilot study. Cytokine 2013;62:389-94.
37. Birbian N, Singh J, Jindal SK, Joshi A, Batra N, Singla N. Association of the wild-Type A/A genotype of MBL2 codon 54 with asthma in a north Indian population. Dis Markers 2012;32:301-8.
38. Liang S, Wei X, Gong C, Wei J, Chen Z, Chen X, et al. Significant association between asthma risk and the GSTM1 and GSTT1 deletion polymorphisms: An updated meta-Analysis of case-control studies. Respirology 2013; 18: 774-83.
39. Nagarkatti R, B Rao C, Rishi JP, Chetiwal R, Shandilya V, Vijayan V, et al. Association of IFNG gene polymorphism with asthma in the Indian population. J Allergy Clin Immunol 2002;110:410-2.
40. Sharma M, Batra J, Mabalirajan U, Sharma S, Nagarkatti R, Aich J, et al. A genetic variation in inositol polyphosphate 4 phosphatase a enhances susceptibility to asthma. Am J Respir Crit Care Med 2008;177:712-9.
41. Birbian N, Singh J, Jindal SK. Protective role of IL-18-137G/C polymorphism in a North Indian population with asthma: A pilot study. Cytokine 2013;61:188-93.
42. Birbian N, Singh J, Jindal SK, Singla N. Association of b(2)-Adrenergic receptor polymorphisms with asthma in a north Indian population. Lung 2012;190:497-504.
43. Sharma S, Nagarkatti R, B-Rao C, Niphadkar PV, Vijayan V, Sharma SK, et al. A-16-C haplotype in the FcepsilonRIbeta gene confers a higher risk for atopic asthma in the Indian population. Clin Genet 2004;66:417-25.
44. Kim O, Kim BH. Association of asthma symptoms with cigarette smoking and alcohol consumption in Korean adolescents. Nurs Health Sci 2013;15:65-72.
45. Strachan DP, Cook DG. Health effects of passive smoking. 6. Parental smoking and childhood asthma: Longitudinal and case-control studies. Thorax 1998;53:204-12.
46. Pokharel PK, Kabra SK, Kapoor SK, Pandey RM. Risk factors associated with bronchial asthma in school going children of rural Haryana. Indian J Pediatr 2001;68:103-6.
47. Mitchell EA, Beasley R, Keil U, Montefort S, Odhiambo J; ISAAC Phase Three Study Group. The association between tobacco and the risk of asthma, rhinoconjunctivitis and eczema in children and adolescents: Analyses from phase three of the ISAAC programme. Thorax 2012;67:941-9.
48. Ehrlich RI, Du Toit D, Jordaan E, Zwarenstein M, Potter P, Volmink JA, et al. Risk factors for childhood asthma and wheezing. Importance of maternal and household smoking. Am J Respir Crit Care Med 1996;154:681-8.
49. He QQ, Wong TW, Du L, Jiang ZQ, Yu TS, Qiu H, et al. Environmental tobacco smoke exposure and Chinese schoolchildrens respiratory health: A prospective cohort study. Am J Prev Med 2011;41:487-93.
50. De Luca G, Olivieri F, Melotti G, Aiello G, Lubrano L, Boner AL. Fetal and early postnatal life roots of asthma. J Matern Fetal Neonatal Med 2010; 23 Suppl 3:80-3.
51. Gupta D, Aggrawal AN, Chaudary J, Jindal SK. Domestic fuel combustion and morbidity from asthma among non-smoking women. Lung India 1999;17:10-4.
52. Agrawal S. Effect of indoor air pollution from biomass and solid fuel combustion on prevalence of self-reported asthma among adult men and women in India: Findings from a nationwide large-scale cross-sectional survey. J Asthma 2012;49:355-65.
53. Mishra V. Effect of indoor air pollution from biomass combustion on prevalence of asthma in the elderly. Environ Health Perspect 2003;111:71-8.
54. Trevor J, Antony V, Jindal SK. The effect of biomass fuel exposure on the prevalence of asthma in adults in India-review of current evidence. J Asthma 2014;51:136-41.
55. Guddattu V, Swathi A, Nair NS. Household and environment factors associated with asthma among Indian women: A multilevel approach. J Asthma 2010;47:407-11.
56. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000;161:1501-7.
57. Sly PD, Kusel M, Holt PG. Do early-life viral infections cause asthma?. J Allergy Clin Immunol 2010;125:1202-5.
58. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999;354:541-5.
59. Robinson DS, Larche M, Durham SR. Tregs and allergic disease. J Clin Invest 2004; 114: 1389-97.
60. Malo JL, Lemiere C, Gautrin D, Labrecque M. Occupational asthma. Curr Opin Pulm Med 2004;10:57-61.
61. Silvers KM, Frampton CM, Wickens K, Pattemore PK, Ingham T, Fishwick D, et al.; New Zealand Asthma and Allergy Cohort Study Group. Breastfeeding protects against current asthma up to 6 years of age. J Pediatr 2012;160:991-6.e1.
62. Friedman NJ, Zeiger RS. The role of breast-feeding in the development of allergies and asthma. J Allergy Clin Immunol 2005;115:1238-48.
63. Kumar R, Kumari D, Srivastava P, Khare V, Fakhr H, Arora N, et al. Identification of IgE-mediated food allergy and allergens in older children and adults with asthma and allergic rhinitis. Indian J Chest Dis Allied Sci 2010;52:217-24.
64. Kumar R, Srivastava P, Kumari D, Fakhr H, Sridhara S, Arora N, et al. Rice (Oryza sativa) allergy in rhinitis and asthma patients: A clinico-immunological study. Immunobiology 2007;212:141-7.
65. Kumari D, Kumar R, Sridhara S, Arora N, Gaur SN, Singh BP. Sensitization to blackgram in patients with bronchial asthma and rhinitis: Clinical evaluation and characterization of allergens. Allergy 2006;61:104-10.
66. Kasera R, Singh BP, Lavasa S, Prasad KN, Sahoo RC, Singh AB. Kidney bean: A major sensitizer among legumes in asthma and rhinitis patients from India. PLoS One 2011;6:e27193.
67. Beuther DA, Sutherland ER. Overweight, obesity, and incident asthma: A meta-Analysis of prospective epidemiologic studies. Am J Respir Crit Care Med 2007;175:661-6.
68. Gupta P. Asthma in the obese: Yet another reason to lose weight. Lung India 2008;25:1-3.
69. Brashier B, Salvi S. Obesity and asthma: Physiological perspective. J Allergy (Cairo) 2013;2013:198068.
70. Vernon MK, Wiklund I, Bell JA, Dale P, Chapman KR. What do we know about asthma triggers?. A review of the literature. J Asthma 2012;49:991-8.
71. Singh M, Das RR, Kumar L, Kumar R. Bacille Calmette-Guerin vaccination is associated with lower prevalence of allergic diseases in Indian children. Am J Rhinol Allergy 2013;27:e107-12.
72. Ryu JH, Scanlon PD. Obstructive lung diseases: COPD, asthma, and many imitators. Mayo Clin Proc 2001;76:1144-53.
73. British Thoracic Society Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 2008;63 Suppl 4:iv1-121.
74. Gupta D, Agarwal R, Aggarwal AN, Maturu VN, Dhooria S, Prasad KT, et al.; S K Jindal for the COPD Guidelines Working Group. Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations. Lung India 2013;30:228-67.
75. Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ, Isonaka S, Nonikov D, et al. Symptom-based questionnaire for differentiating COPD and asthma. Respiration 2006;73:296-305.
76. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA) 2014. Available from: http://www.ginasthma. org/. [Last accessed on 2014 Jun 24].
77. Mathew JL, Singh M, Mittal SK. Gastro-oesophageal reflux and bronchial asthma: Current status and future directions. Postgrad Med J 2004;80:701-5.
78. Jindal A, Bal A, Agarwal R. Inflammatory myofibroblastic tumor of the trachea in the pediatric age group: Case report and systematic review of the literature. J Bronchology Interv Pulmonol 2015;22:58-65.
79. Pratter MR. Overview of common causes of chronic cough: ACCP evidence-based clinical practice guidelines. Chest 2006;129(Suppl):59s-62s.
80. Benninger C, Parsons JP, Mastronarde JG. Vocal cord dysfunction and asthma. Curr Opin Pulm Med 2011;17:45-9.
81. Newman KB, Mason UG 3rd, Schmaling KB. Clinical features of vocal cord dysfunction. Am J Respir Crit Care Med 1995;152:1382-6.
82. Killian KJ, Watson R, Otis J, St Amand TA, OByrne PM. Symptom perception during acute bronchoconstriction. Am J Respir Crit Care Med 2000;162:490-6.
83. Ekici M, Apan A, Ekici A, Erdemoʇlu AK. Perception of bronchoconstriction in elderly asthmatics. J Asthma 2001;38:691-6.
84. van Schayck CP, van Der Heijden FM, van Den Boom G, Tirimanna PR, van Herwaarden CL. Underdiagnosis of asthma: Is the doctor or the patient to blame?. The DIMCA project. Thorax 2000;55:562-5.
85. Standardization of spirometry, 1994 update. American Thoracic Society. Am J Respir Crit Care Med 1995;152:1107-36.
86. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al.; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 2005;26:319-38.
87. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26:948-68.
88. Aggarwal AN. How appropriate is the gold standard for diagnosis of airway obstruction?. Lung India 2008;25:139-41.
89. Jain SK, Ramiah TJ. Spirometric studies in healthy women 15-40 years age. Indian J Chest Dis 1967;9:1-12.
90. Jain SK, Ramiah TJ. Normal standards of pulmonary function tests for healthy Indian men 15-40 years old: Comparison of different regression equations (prediction formulae). Indian J Med Res 1969;57:1453-66.
91. Jindal SK, Wahi PL. Pulmonary function laboratory in the tropics, needs, problems, and solutions. In: Sharma OP, editor. Lung Disease in the Tropics. New York: Marcel Dekker; 1991. p. 523-42.
92. Udwadia FE, Sunavala JD, Shetye VM. Lung function studies in healthy Indian subjects. J Assoc Physicians India 1987;35:491-6.
93. Vijayan VK, Kuppurao KV, Venkatesan P, Sankaran K, Prabhakar R. Pulmonary function in healthy young adult Indians in Madras. Thorax 1990;45:611-5.
94. Aggarwal AN, Gupta D, Jindal SK. Development of a simple computer program for spirometry interpretation. J Assoc Physicians India 2002;50:567-70.
95. Kupczyk M, Kuprys I, Gorski P, Kuna P. Long-Term deterioration of lung function in asthmatic outpatients. Respiration 2004;71:233-40.
96. Kitch BT, Paltiel AD, Kuntz KM, Dockery DW, Schouten JP, Weiss ST, et al. A single measure of FEV1 is associated with risk of asthma attacks in long-Term follow-up. Chest 2004;126:1875-82.
97. Pino JM, Garcia-Rio F, Prados C, Alvarez-Sala R, Díaz S, Villasante C, et al. Value of the peak expiratory flow in bronchodynamic tests. Allergol Immunopathol (Madr) 1996;24:54-7.
98. Dekker FW, Schrier AC, Sterk PJ, Dijkman JH. Validity of peak expiratory flow measurement in assessing reversibility of airflow obstruction. Thorax 1992;47:162-6.
99. Aggarwal AN, Agarwal R, Gupta D, Jindal SK. Use of peak expiratory flow for assessing bronchodilator responsiveness. Prim Care Respir J 2009;18:50-2.
100. Ray D, Rajaratnam A, Richard J. Peak expiratory flow in rural residents of Tamil Nadu, India. Thorax 1993;48:163-6.
101. Kaur H, Singh J, Makkar M, Singh K, Garg R. Variations in the peak expiratory flow rate with various factors in a population of healthy women of the malwa region of Punjab, India. J Clin Diagn Res 2013;7:1000-3.
102. Mittal S, Gupta S, Kumar A, Singh KD. Regression equations for peak expiratory flow in healthy children aged 7 to 14 years from Punjab, India. Lung India 2013;30:183-6.
103. Oga T, Nishimura K, Tsukino M, Hajiro T, Ikeda A. A comparison of the individual best versus the predicted peak expiratory flow in patients with chronic asthma. J Asthma 2001;38:33-40.
104. Malik SK, Jindal SK, Banga N, Sharda PK, Gupta HD. Peak expiratory flow rate of healthy north Indian teachers. Indian J Med Res 1980;71:322-4.
105. Malik SK, Jindal SK, Sharda PK, Banga N. Peak expiratory flow rates of school age girls from Punjab (Second report). Indian Pediatr 1982;19:161-4.
106. Malik SK, Jindal SK. Pulmonary function tests in healthy children. Indian Pediatr 1985;22:677-81.
107. Vijayan VK, Reetha AM, Kuppurao KV, Venkatesan P, Thilakavathy S. Pulmonary function in normal south Indian children aged 7 to 19 years. Indian J Chest Dis Allied Sci 2000;42:147-56.
108. Bongers T, ODriscoll BR. Effects of equipment and technique on peak flow measurements. BMC Pulm Med 2006;6:14.
109. Malik SK, Jindal SK, Banga N. Experience with Wrights new mini peak flow meter for monitoring airways obstruction. Indian J Chest Dis Allied Sci 1980;22:220-3.
110. Slieker MG, van der Ent CK. The diagnostic and screening capacities of peak expiratory flow measurements in the assessment of airway obstruction and bronchodilator response in children with asthma. Monaldi Arch Chest Dis 2003;59:155-9.
111. Aggarwal AN, Gupta D, Jindal SK. The relationship between FEV1 and peak expiratory flow in patients with airways obstruction is poor. Chest 2006;130:1454-61.
112. Llewellin P, Sawyer G, Lewis S, Cheng S, Weatherall M, Fitzharris P, et al. The relationship between FEV1 and PEF in the assessment of the severity of airways obstruction. Respirology 2002;7:333-7.
113. Palma-Carlos AG, Palma-Carlos ML. Correlation between clinical classification, PEF and FEV1: Guidelines and reality. Eur Ann Allergy Clin Immunol 2003;35:130-2.
114. Hetzel MR. The pulmonary clock. Thorax 1981;36:481-6.
115. Hetzel MR, Clark TJ. Comparison of normal and asthmatic circadian rhythms in peak expiratory flow rate. Thorax 1980;35:732-8.
116. Aggarwal AN, Gupta D, Chaganti S, Jindal SK. Diurnal variation in peak expiratory flow in healthy young adults. Indian J Chest Dis Allied Sci 2000;42:15-9.
117. Aggarwal AN, Gupta D, Kumar V, Jindal SK. Assessment of diurnal variability of peak expiratory flow in stable asthmatics. J Asthma 2002;39:487-91.
118. Gupta D, Aggarwal AN, Chaganti S, Jindal SK. Reducing the number of daily measurements results in poor estimation of diurnal variability of peak expiratory flow in healthy individuals. J Postgrad Med 2000;46:262-4.
119. Higgins BG, Britton JR, Chinn S, Jones TD, Jenkinson D, Burney PG, et al. The distribution of peak expiratory flow variability in a population sample. Am Rev Respir Dis 1989;140:1368-72.
120. Boushey HA, Holtzman MJ, Sheller JR, Nadel JA. Bronchial hyperreactivity. Am Rev Respir Dis 1980;121:389-413.
121. Aggarwal AN, Gupta D, Chandrasekhar G, Jindal SK. Bronchial hyperresponsiveness in patients with sarcoidosis. J Assoc Physicians India 2004;52:21-3.
122. Perpiñá Tordera M, García Río F, Álvarez Gutierrez FJ, Cisneros Serrano C, Compte Torrero L, Entrenas Costa LM, et al.; Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Guidelines for the study of nonspecific bronchial hyperresponsiveness in asthma. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Arch Bronconeumol 2013;49:432-46.
123. Cockcroft D, Davis B. Direct and indirect challenges in the clinical assessment of asthma. Ann Allergy Asthma Immunol 2009;103:363-72, 400.
124. Cockcroft DW. Direct challenge tests: Airway hyperresponsiveness in asthma: Its measurement and clinical significance. Chest 2010;138(Suppl):18s-24s.
125. Goldstein MF, Veza BA, Dunsky EH, Dvorin DJ, Belecanech GA, Haralabatos IC. Comparisons of peak diurnal expiratory flow variation, postbronchodilator FEV (1) responses and methacholine inhalation challenges in the evaluation of suspected asthma. Chest 2001;119:1001-10.
126. Anderson SD, Charlton B, Weiler JM, Nichols S, Spector SL, Pearlman DS; A305 Study Group. Comparison of mannitol and methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthma. Respir Res 2009;10:4.
127. Ernst P, Ghezzo H, Becklake MR. Risk factors for bronchial hyperresponsiveness in late childhood and early adolescence. Eur Respir J 2002;20:635-9.
128. Remes ST, Pekkanen J, Remes K, Salonen RO, Korppi M. In search of childhood asthma: Questionnaire, tests of bronchial hyperresponsiveness and clinical evaluation. Thorax 2002;57:120-6.
129. Pekkanen J, Pearce N. Defining asthma in epidemiological studies. Eur Respir J 1999;14:951-7.
130. Agarwal R. Allergic bronchopulmonary aspergillosis. Chest 2009;135:805-26.
131. Agarwal R, Khan A, Garg M, Aggarwal AN, Gupta D. Pictorial essay: Allergic bronchopulmonary aspergillosis. Indian J Radiol Imaging 2011;21:242-52.
132. Hederos CA, Janson S, Andersson H, Hedlin G. Chest X-ray investigation in newly discovered asthma. Pediatr Allergy Immunol 2004;15:163-5.
133. Gershel JC, Goldman HS, Stein RE, Shelov SP, Ziprkowski M. The usefulness of chest radiographs in first asthma attacks. N Engl J Med 1983;309:336-9.
134. Rubenstein HS, Rosner BA, LeMay M, Neidorf R. The value of the chest X-ray in making the diagnosis of bronchial asthma. Adolescence 1993;28:505-16.
135. Castro M, Fain SB, Hoffman EA, Gierada DS, Erzurum SC, Wenzel S; National Heart, Lung, and Blood Institutes Severe Asthma Research Program. Lung imaging in asthmatic patients: The picture is clearer. J Allergy Clin Immunol 2011;128:467-78.
136. Good JT Jr, Kolakowski CA, Groshong SD, Murphy JR, Martin RJ. Refractory asthma: Importance of bronchoscopy to identify phenotypes and direct therapy. Chest 2012;141:599-606.
137. Tseliou E, Bessa V, Hillas G, Delimpoura V, Papadaki G, Roussos C, et al. Exhaled nitric oxide and exhaled breath condensate pH in severe refractory asthma. Chest 2010;138:107-13.
138. Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, et al.; Bronchoscopic Exploratory Research Study of Biomarkers in Corticosteroid-refractory Asthma (BOBCAT) Study Group. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012;130:647-54. e10.
139. Wadsworth S, Sin D, Dorscheid D. Clinical update on the use of biomarkers of airway inflammation in the management of asthma. J Asthma Allergy 2011;4:77-86.
140. Bush A, Eber E. The value of FeNO measurement in asthma management: The motion for Yes, its NO-or, the wrong end of the stick! Paediatr Respir Rev 2008;9:127-31.
141. Nair P. Update on clinical inflammometry for the management of airway diseases. Can Respir J 2013;20:117-20.
142. Djukanović R, Sterk PJ, Fahy JV, Hargreave FE. Standardised methodology of sputum induction and processing. Eur Respir J Suppl 2002;37:1s-2s.
143. Paggiaro PL, Chanez P, Holz O, Ind PW, Djukanović R, Maestrelli P, et al. Sputum induction. Eur Respir J Suppl 2002;37:3s-8s.
144. Efthimiadis A, Spanevello A, Hamid Q, Kelly MM, Linden M, Louis R, et al. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. Eur Respir J Suppl 2002;37:19s-23s.
145. Spanevello A, Confalonieri M, Sulotto F, Romano F, Balzano G, Migliori GB, et al. Induced sputum cellularity. Reference values and distribution in normal volunteers. Am J Respir Crit Care Med 2000;162:1172-4.
146. Hunter CJ, Brightling CE, Woltmann G, Wardlaw AJ, Pavord ID. A comparison of the validity of different diagnostic tests in adults with asthma. Chest 2002;121:1051-7.
147. Petsky HL, Cates CJ, Lasserson TJ, Li AM, Turner C, Kynaston JA, et al. A systematic review and meta-Analysis: Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012;67:199-208.
148. Hargreave FE, Nair P. Point: Is measuring sputum eosinophils useful in the management of severe asthma?. Yes. Chest 2011;139:1270-3.
149. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-6.
150. Stewart L, Katial RK. Exhaled nitric oxide. Immunol Allergy Clin North Am 2012;32:347-62.
151. Nathan C, Xie QW. Nitric oxide synthases: Roles, tolls and controls. Cell 1994;78:915-8.
152. Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J 1993;6:1368-70.
153. Dweik RA, Comhair SA, Gaston B, Thunnissen FB, Farver C, Thomassen MJ, et al. NO chemical events in the human airway during the immediate and late antigen-induced asthmatic response. Proc Natl Acad Sci U S A 2001;98:2622-7.
154. Berry M, Morgan A, Shaw DE, Parker D, Green R, Brightling C, et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 2007;62:1043-9.
155. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al.; American Thoracic Society Committee onInterpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: Interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011;184:602-15.
156. Petsky HL, Cates CJ, Li A, Kynaston JA, Turner C, Chang AB. Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev 2009; CD006340.
157. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al.; National Heart, Lung and Blood Institutes Severe Asthma Research Program. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med 2010;181:315-23.
158. Schatz M, Hsu JW, Zeiger RS, Chen W, Dorenbaum A, Chipps BE, et al. Phenotypes determined by cluster analysis in severe or difficult-To-Treat asthma. J Allergy Clin Immunol 2014;133:1549-56.
159. Weinmayr G, Keller F, Kleiner A, du Prel JB, Garcia-Marcos L, Batlles-Garrido J, et al. Asthma phenotypes identified by latent class analysis in the ISAAC phase II Spain study. Clin Exp Allergy 2013;43:223-32.
160. Schwindt CD, Tjoa T, Floro JN, McLaren C, Delfino RJ. Association of atopy to asthma severity and medication use in children. J Asthma 2006;43:439-46.
161. Carroll WD, Lenney W, Child F, Strange RC, Jones PW, Whyte MK, et al. Asthma severity and atopy: How clear is the relationship?. Arch Dis Child 2006;91:405-9.
162. Rasmussen F, Taylor DR, Flannery EM, Cowan JO, Greene JM, Herbison GP, et al. Risk factors for hospital admission for asthma from childhood to young adulthood: A longitudinal population study. J Allergy Clin Immunol 2002;110:220-7.
163. Ponte EV, Souza-Machado A, Souza-Machado C, Franco R, Cruz AA. Atopy is not associated with poor control of asthma. J Asthma 2012;49:1021-6.
164. Ozol D, Koca C, Mete E, Yigitoʇlu R. Influence of atopy on asthma severity in adult female patients. J Investig Allergol Clin Immunol 2008;18:36-40.
165. Agarwal R, Chakrabarti A. Allergic bronchopulmonary aspergillosis in asthma: Epidemiological, clinical and therapeutic issues. Future Microbiol 2013;8:1463-74.
166. Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, et al. A new perspective on concepts of asthma severity and control. Eur Respir J 2008;32:545-54.
167. Cockcroft DW, Swystun VA. Asthma control versus asthma severity. J Allergy Clin Immunol 1996;98:1016-8.
168. Lougheed MD, Lemiere C, Ducharme FM, Licskai C, Dell SD, Rowe BH, et al.; Canadian Thoracic Society Asthma Clinical Assembly. Canadian Thoracic Society 2012 guideline update: Diagnosis and management of asthma in preschoolers, children and adults. Can Respir J 2012;19:127-64.
169. Executive Committee Gema 2009. GEMA 2009 (Spanish guideline on the management of asthma). J Investig Allergol Clin Immunol 2010;20 Suppl 1:1-59.
170. Adams NP, Bestall JC, Jones P. Budesonide versus placebo for chronic asthma in children and adults. Cochrane Database Syst Rev 1999;CD003274.
171. Adams NP, Bestall JC, Lasserson TJ, Jones P, Cates CJ. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev 2008;CD003135.
172. Adams NP, Bestall JB, Malouf R, Lasserson TJ, Jones PW. Inhaled beclomethasone versus placebo for chronic asthma. Cochrane Database Syst Rev 2005;CD002738.
173. Manning P, Gibson PG, Lasserson TJ. Ciclesonide versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev 2008;CD006217.
174. Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF Jr, Sorkness CA, et al.; Asthma Clinical Research Network for the National Heart, Lung and Blood Institute. Long-Acting beta2-Agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: A randomized controlled trial. JAMA 2001;285:2583-93.
175. Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2012;5:CD002314.
176. Youngchaiyud P, Permpikul C, Suthamsmai T, Wong E. A double-blind comparison of inhaled budesonide, long-Acting theophylline and their combination in treatment of nocturnal asthma. Allergy 1995;50:28-33.
177. Reed CE, Offord KP, Nelson HS, Li JT, Tinkelman DG. Aerosol beclomethasone dipropionate spray compared with theophylline as primary treatment for chronic mild-To-moderate asthma. The American Academy of Allergy, Asthma and Immunology Beclomethasone Dipropionate-Theophylline Study Group. J Allergy Clin Immunol 1998;101:14-23.
178. Morali T, Yilmaz A, Erkan F, Akkaya E, Ece F, Baran R. Efficacy of inhaled budesonide and oral theophylline in asthmatic subjects. J Asthma 2001;38:673-9.
179. Tinkelman DG, Reed CE, Nelson HS, Offord KP. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics 1993;92:64-77.
180. Dahl R, Larsen BB, Venge P. Effect of long-Term treatment with inhaled budesonide or theophylline on lung function, airway reactivity and asthma symptoms. Respir Med 2002;96:432-8.
181. Yurdakul AS, Taci N, Eren A, Sipit T. Comparative efficacy of once-daily therapy with inhaled corticosteroid, leukotriene antagonist or sustained-release theophylline in patients with mild persistent asthma. Respir Med 2003;97:1313-9.
182. Stoloff SW, Kelly HW. Updates on the use of inhaled corticosteroids in asthma. Curr Opin Allergy Clin Immunol 2011;11:337-44.
183. Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, et al.; Asthma Clinical Research Network of the National Heart Lung, and Blood Institute. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002;109:410-8.
184. Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: Meta-Analysis. BMJ 2001;323:253-6.
185. Masoli M, Weatherall M, Holt S, Beasley R. Clinical dose-response relationship of fluticasone propionate in adults with asthma. Thorax 2004;59:16-20.
186. Adams N, Bestall J, Jones PW. Budesonide at different doses for chronic asthma. Cochrane Database Syst Rev 2001;CD003271.
187. Powell H, Gibson PG. High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children. Cochrane Database Syst Rev 2004;CD004109.
188. Adams NP, Bestall JC, Jones P, Lasserson TJ, Griffiths B, Cates CJ. Fluticasone at different doses for chronic asthma in adults and children. Cochrane Database Syst Rev 2008;CD003534.
189. Calhoun WJ, Ameredes BT, King TS, Icitovic N, Bleecker ER, Castro M, et al.; Asthma Clinical Research Network of the National Heart, Lung, and Blood Institute. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: The BASALT randomized controlled trial. JAMA 2012;308:987-97.
190. Papi A, Canonica GW, Maestrelli P, Paggiaro P, Olivieri D, Pozzi E, et al.; BEST Study Group. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med 2007;356:2040-52.
191. Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV, Lazarus SC, et al.; National Heart, Lung and Blood Institutes Asthma Clinical Research Network. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005;352:1519-28.
192. Chauhan BF, Chartrand C, Ducharme FM. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database Syst Rev 2013;2:CD009611.
193. Baptist AP, Reddy RC. Inhaled corticosteroids for asthma: Are they all the same?. J Clin Pharm Ther 2009;34:1-12.
194. Adams N, Bestall JM, Jones PW. Inhaled beclomethasone versus budesonide for chronic asthma. Cochrane Database Syst Rev 2002;CD003530.
195. Adams N, Lasserson TJ, Cates CJ, Jones PW. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev 2007;CD002310.
196. Manning P, Gibson PG, Lasserson TJ. Ciclesonide versus other inhaled steroids for chronic asthma in children and adults. Cochrane Database Syst Rev 2008;CD007031.
197. Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy 2006;61:518-26.
198. Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: Current understanding and review of the literature. Chest 2004;126:213-9.
199. Berger WE. Ciclesonide: A closer look at its systemic and oropharyngeal safety profile. Curr Drug Saf 2006;1:265-70.
200. Todd GR, Acerini CL, Ross-Russell R, Zahra S, Warner JT, McCance D. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002;87:457-61.
201. Lapi F, Kezouh A, Suissa S, Ernst P. The use of inhaled corticosteroids and the risk of adrenal insufficiency. Eur Respir J 2013;42:79-86.
202. Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med 2006;100:1307-17.
203. Vogelmeier CF, Hering T, Lewin T, Sander P, Bethke TD. Efficacy and safety of ciclesonide in the treatment of 24, 037 asthmatic patients in routine medical care. Respir Med 2011;105:186-94.
204. McKeever T, Harrison TW, Hubbard R, Shaw D. Inhaled corticosteroids and the risk of pneumonia in people with asthma: A case-control study. Chest 2013;144:1788-94.
205. Lee CH, Kim K, Hyun MK, Jang EJ, Lee NR, Yim JJ. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax 2013;68:1105-13.
206. Sharma PK, Malhotra S, Pandhi P, Kumar N. Effect of inhaled steroids on bone mineral density: A meta-Analysis. J Clin Pharmacol 2003;43:193-7.
207. Uboweja A, Malhotra S, Pandhi P. Effect of inhaled corticosteroids on risk of development of cataract: A meta-Analysis. Fundam Clin Pharmacol 2006;20:305-9.
208. Khianey R, Oppenheimer J. Controversies regarding long-Acting s2-Agonists. Curr Opin Allergy Clin Immunol 2011;11:345-54.
209. Walters EH, Gibson PG, Lasserson TJ, Walters JA. Long-Acting beta2-Agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database Syst Rev 2007;CD001385.
210. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26.
211. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: Comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993;306:1034-7.
212. Lemanske RF Jr, Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, Fahy JV, et al.; Asthma Clinical Research Network for the National Heart, Lung, and Blood Institute. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: A randomized controlled trial. JAMA 2001;285:2594-603.
213. Weatherall M, Wijesinghe M, Perrin K, Harwood M, Beasley R. Meta-Analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. Thorax 2010;65:39-43.
214. Nelson H, Bonuccelli C, Radner F, Ottosson A, Carroll KJ, Andersson TL, et al. Safety of formoterol in patients with asthma: Combined analysis of data from double-blind, randomized controlled trials. J Allergy Clin Immunol 2010;125:390-6. e8.
215. Cates CJ, Wieland LS, Oleszczuk M, Kew KM. Safety of regular formoterol or salmeterol in adults with asthma: An overview of Cochrane reviews. Cochrane Database Syst Rev 2014;2:CD010314.
216. OByrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: The OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164:1392-7.
217. Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, OByrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405-11.
218. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al.; GOAL Investigators Group. Can guideline-defined asthma control be achieved?. The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170:836-44.
219. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-Acting beta2-Agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev 2010;CD005535.
220. Cates CJ, Lasserson TJ. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: Serious adverse events. Cochrane Database Syst Rev 2010;CD007694.
221. Lasserson TJ, Ferrara G, Casali L. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database Syst Rev 2011;CD004106.
222. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-Acting beta2-Agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev 2010;CD005533.
223. Adachi M, Aizawa H, Ishihara K, Ohta K, Sano Y, Taniguchi H, et al. Comparison of salmeterol/fluticasone propionate (FP) combination with FP+sustained release theophylline in moderate asthma patients. Respir Med 2008;102:1055-64.
224. Ducharme FM, Lasserson TJ, Cates CJ. Addition to inhaled corticosteroids of long-Acting beta2-Agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev 2011;CD003137.
225. OByrne PM, Bleecker ER, Bateman ED, Busse WW, Woodcock A, Forth R, et al. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur Respir J 2014;43:773-82.
226. Bateman ED, OByrne PM, Busse WW, Lötvall J, Bleecker ER, Andersen L, et al. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax 2014;69:312-9.
227. Woodcock A, Bleecker ER, Lötvall J, OByrne PM, Bateman ED, Medley H, et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: A randomized trial. Chest 2013;144:1222-9.
228. Kempsford RD, Oliver A, Bal J, Tombs L, Quinn D. The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respir Med 2013;107:1873-80.
229. Lipworth B. Systemic safety of fluticasone furoate/vilanterol combination. Thorax 2013;68:1165.
230. Allen A, Schenkenberger I, Trivedi R, Cole J, Hicks W, Gul N, et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-Adrenal axis function in adolescent and adult asthma: Randomised, double-blind, placebo-controlled study. Clin Respir J 2013;7:397-406.
231. Busse WW, OByrne PM, Bleecker ER, Lötvall J, Woodcock A, Andersen L, et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the b2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: A randomised trial. Thorax 2013;68:513-20.
232. Kanniess F, Boulet LP, Pierzchala W, Cameron R, Owen R, Higgins M. Efficacy and safety of indacaterol, a new 24-hour beta2-Agonist, in patients with asthma: A dose-ranging study. J Asthma 2008;45:887-92.
233. Sugihara N, Kanada S, Haida M, Ichinose M, Adachi M, Hosoe M, et al. 24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: A comparison with placebo and salmeterol. Respir Med 2010;104:1629-37.
234. Gibb A, Yang LP. Olodaterol: First global approval. Drugs 2013;73:1841-6.
235. Vignola AM. Effects of inhaled corticosteroids, leukotriene receptor antagonists, or both, plus long-Acting beta2-Agonists on asthma pathophysiology: A review of the evidence. Drugs 2003;63 Suppl 2:35-51.
236. Bel EH. Clinical practice. Mild asthma. N Engl J Med 2013;369:549-57.
237. Barnes ML, Menzies D, Fardon TC, Burns P, Wilson AM, Lipworth BJ. Combined mediator blockade or topical steroid for treating the unified allergic airway. Allergy 2007;62:73-80.
238. Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clin Exp Allergy 2001;31:616-24.
239. Wilson AM, Orr LC, Sims EJ, Dempsey OJ, Lipworth BJ. Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma. Am J Respir Crit Care Med 2000;162:1297-301.
240. Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims EJ, Gilbert RF, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011;364:1695-707.
241. Ducharme F, Schwartz Z, Hicks G, Kakuma R. Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2004;CD003133.
242. Dupont L, Potvin E, Korn D, Lachman A, Dramaix M, Gusman J, et al.; Singulair as Complementary Therapy to Fixed Association in Real life Study Group. Improving asthma control in patients suboptimally controlled on inhaled steroids and long-Acting beta2-Agonists: Addition of montelukast in an open-label pilot study. Curr Med Res Opin 2005;21:863-9.
243. Korn D, Van den Brande P, Potvin E, Dramaix M, Herbots E, Peche R. Efficacy of add-on montelukast in patients with non-controlled asthma: A Belgian open-label study. Curr Med Res Opin 2009;25:489-97.
244. Virchow JC, Bachert C. Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respir Med 2006;100:1952-9.
245. Virchow JC, Mehta A, Ljungblad L, Mitfessel H, MONICA Study Group. Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: The MONtelukast In Chronic Asthma (MONICA) study. Respir Med 2010;104:644-51.
246. Sadatsafavi M, Lynd L, Marra C, Bedouch P, Fitzgerald M. Comparative outcomes of leukotriene receptor antagonists and long-Acting s-Agonists as add-on therapy in asthmatic patients: A population-based study. J Allergy Clin Immunol 2013;132:63-9.
247. Joos S, Miksch A, Szecsenyi J, Wieseler B, Grouven U, Kaiser T, et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: A systematic review. Thorax 2008;63:453-62.
248. Barnes N, Thomas M, Price D, Tate H. The national montelukast survey. J Allergy Clin Immunol 2005;115:47-54.
249. Price D. Tolerability of montelukast. Drugs 2000;59 Suppl 1:35-45.
250. Guyer AC, Long AA. Long-Acting anticholinergics in the treatment of asthma. Curr Opin Allergy Clin Immunol 2013;13:392-8.
251. Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol 2011;128:315-22.
252. Peters SP, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, et al.; National Heart, Lung, and Blood Institute Asthma Clinical Research Network. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010;363:1715-26.
253. Kerstjens HA, Disse B, Schroder-Babo W, Bantje TA, Gahlemann M, Sigmund R, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial. J Allergy Clin Immunol 2011;128:308-14.
254. Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012;367:1198-207.
255. Tian JW, Chen JW, Chen R, Chen X. Tiotropium versus placebo for inadequately controlled asthma: A meta-Analysis. Respir Care 2014;59:654-66.
256. Barnes PJ. Theophylline. Am J Respir Crit Care Med 2013;188:901-6.
257. Tee AK, Koh MS, Gibson PG, Lasserson TJ, Wilson AJ, Irving LB. Long-Acting beta2-Agonists versus theophylline for maintenance treatment of asthma. Cochrane Database Syst Rev 2007;CD001281.
258. Davies B, Brooks G, Devoy M. The efficacy and safety of salmeterol compared to theophylline: Meta-Analysis of nine controlled studies. Respir Med 1998;92:256-63.
259. Dempsey OJ, Fowler SJ, Wilson A, Kennedy G, Lipworth BJ. Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma. Chest 2002;122:151-9.
260. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, OConnor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997;337:1412-8.
261. Lim S, Jatakanon A, Gordon D, Macdonald C, Chung KF, Barnes PJ. Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practice. Thorax 2000;55:837-41.
262. Ukena D, Harnest U, Sakalauskas R, Magyar P, Vetter N, Steffen H, et al. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J 1997;10:2754-60.
263. American Lung Association Asthma Clinical Research Centers. Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med 2007;175:235-42.
264. Nie H, Zhang G, Liu M, Ding X, Huang Y, Hu S. Efficacy of theophylline plus salmeterol/fluticasone propionate combination therapy in patients with asthma. Respir Med 2013;107:347-54.
265. Shukla D, Chakraborty S, Singh S, Mishra B. Doxofylline: A promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opin Pharmacother 2009;10:2343-56.
266. Goldstein MF, Chervinsky P. Efficacy and safety of doxofylline compared to theophylline in chronic reversible asthma-A double-blind randomized placebo-controlled multicentre clinical trial. Med Sci Monit 2002;8:CR297-304.
267. Melillo G, Balzano G, Jodice F, De Felice A, Campisi V, Capone M, et al. Treatment of reversible chronic airways obstruction with doxofylline compared with slow-release theophylline: A double-blind, randomized, multicentre trial. Int J Clin Pharmacol Res 1989;9:397-405.
268. Welsh EJ, Cates CJ. Formoterol versus short-Acting beta-Agonists as relief medication for adults and children with asthma. Cochrane Database Syst Rev 2010;CD008418.
269. Westby M, Benson M, Gibson P. Anticholinergic agents for chronic asthma in adults. Cochrane Database Syst Rev 2004;CD003269.
270. Agarwal R, Khan A, Aggarwal AN, Gupta D. Is the SMART approach better than other treatment approaches for prevention of asthma exacerbations?. A meta-Analysis. Monaldi Arch Chest Dis 2009;71:161-9.
271. Stallberg B, Ekström T, Neij F, Olsson P, Skoogh BE, Wennergren G, et al.; SHARE Trial Group. A real-life cost-effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respir Med 2008;102:1360-70.
272. Patel M, Pilcher J, Beasley R. Combination ICS/fast-onset LABA inhaler as maintenance and reliever therapy: The future for uncontrolled adult asthma?. Expert Rev Respir Med 2013;7:451-4.
273. Papi A, Corradi M, Pigeon-Francisco C, Baronio R, Siergiejko Z, Petruzzelli S, et al. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: A double-blind, randomised controlled trial. Lancet Respir Med 2013;1:23-31.
274. Sovani MP, Whale CI, Oborne J, Cooper S, Mortimer K, Ekström T, et al. Poor adherence with inhaled corticosteroids for asthma: Can using a single inhaler containing budesonide and formoterol help?. Br J Gen Pract 2008;58:37-43.
275. Scicchitano R, Aalbers R, Ukena D, Manjra A, Fouquert L, Centanni S, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004;20:1403-18.
276. Rabe KF, Pizzichini E, Stallberg B, Romero S, Balanzat AM, Atienza T, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-To-moderate asthma: A randomized, double-blind trial. Chest 2006;129:246-56.
277. OByrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005;171:129-36.
278. Vogelmeier C, DUrzo A, Pauwels R, Merino JM, Jaspal M, Boutet S, et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. Eur Respir J 2005;26:819-28.
279. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: A randomised controlled, double-blind study. Lancet 2006;368:744-53.
280. Lundborg M, Wille S, Bjermer L, Tilling B, Lundgren M, Telg G, et al. Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: An efficacy and cost-effectiveness study. Curr Med Res Opin 2006;22:809-21.
281. Kuna P, Peters MJ, Manjra AI, Jorup C, Naya IP, Martinez-Jimenez NE, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007;61:725-36.
282. Bousquet J, Boulet LP, Peters MJ, Magnussen H, Quiralte J, Martinez-Aguilar NE, et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med 2007;101:2437-46.
283. Patel M, Pilcher J, Pritchard A, Perrin K, Travers J, Shaw D, et al.; SMART Study Group. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: A randomised controlled trial. Lancet Respir Med 2013;1:32-42.
284. Sears MR, Boulet LP, Laviolette M, Fitzgerald JM, Bai TR, Kaplan A, et al. Budesonide/formoterol maintenance and reliever therapy: Impact on airway inflammation in asthma. Eur Respir J 2008;31:982-9.
285. Riemersma RA, Postma D, van der Molen T. Budesonide/formoterol maintenance and reliever therapy in primary care asthma management: Effects on bronchial hyperresponsiveness and asthma control. Prim Care Respir J 2012;21:50-6.
286. Soes-Petersen U, Kava T, Dahle R, Lei Y, Dam N. Budesonide/formoterol maintenance and reliever therapy versus conventional best standard treatment in asthma in an attempted real life setting. Clin Respir J 2011;5:173-82.
287. Louis R, Joos G, Michils A, Vandenhoven G. A comparison of budesonide/ formoterol maintenance and reliever therapy vs. conventional best practice in asthma management. Int J Clin Pract 2009;63:1479-88.
288. Demoly P, Louis R, Soes-Petersen U, Naya I, Carlsheimer A, Worth H, et al. Budesonide/formoterol maintenance and reliever therapy versus conventional best practice. Respir Med 2009;103:1623-32.
289. Zhong N, Lin J, Mehta P, Ngamjanyaporn P, Wu TC, Yunus F. Real-life effectiveness of budesonide/formoterol maintenance and reliever therapy in asthma patients across Asia: SMARTASIA study. BMC Pulm Med 2013;13:22.
290. Aubier M, Buhl R, Ekström T, Ostinelli J, van Schayck CP, Selroos O, et al. Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy. Eur Respir J 2010;36:524-30.
291. Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst Rev 2013;4:CD007313.
292. Kew KM, Karner C, Mindus SM, Ferrara G. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev 2013;12:CD009019.
293. Bateman ED, Clark TJ, Frith L, Bousquet J, Busse WW, Pedersen SE, Goal Investigators Group. Rate of response of individual asthma control measures varies and may overestimate asthma control: An analysis of the goal study. J Asthma 2007;44:667-73.
294. Rogers L, Reibman J. Stepping down asthma treatment: How and when. Curr Opin Pulm Med 2012;18:70-5.
295. Bacharier LB. Step-down therapy in asthma: A focus on treatment options for patients receiving inhaled corticosteroids and long-Acting beta-Agonist combination therapy. Allergy Asthma Proc 2012;33:13-8.
296. Papi A, Nicolini G, Crimi N, Fabbri L, Olivieri D, Rossi A, et al. Step-down from high dose fixed combination therapy in asthma patients: A randomized controlled trial. Respir Res 2012;13:54.
297. Hawkins G, McMahon AD, Twaddle S, Wood SF, Ford I, Thomson NC. Stepping down inhaled corticosteroids in asthma: Randomised controlled trial. BMJ 2003;326:1115.
298. Hagan JB, Samant SA, Volcheck GW, Li JT, Hagan CR, Erwin PJ, et al. The risk of asthma exacerbation after reducing inhaled corticosteroids: A systematic review and meta-Analysis of randomized controlled trials. Allergy 2014;69:510-6.
299. Bateman ED, Jacques L, Goldfrad C, Atienza T, Mihaescu T, Duggan M. Asthma control can be maintained when fluticasone propionate/ salmeterol in a single inhaler is stepped down. J Allergy Clin Immunol 2006;117:563-70.
300. Godard P, Greillier P, Pigearias B, Nachbaur G, Desfougeres JL, Attali V. Maintaining asthma control in persistent asthma: Comparison of three strategies in a 6-month double-blind randomised study. Respir Med 2008;102:1124-31.
301. Reddel HK, Gibson PG, Peters MJ, Wark PA, Sand IB, Hoyos CM, et al. Down-Titration from high-dose combination therapy in asthma: Removal of long-Acting beta (2)-Agonist. Respir Med 2010;104:1110-20.
302. Koenig SM, Ostrom N, Pearlman D, Waitkus-Edwards K, Yancey S, Prillaman BA, et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are stepped-down. J Asthma 2008;45:681-7.
303. Berger WE, Bleecker ER, ODowd L, Miller CJ, Mezzanotte W. Efficacy and safety of budesonide/formoterol pressurized metered-dose inhaler: Randomized controlled trial comparing once-And twice-daily dosing in patients with asthma. Allergy Asthma Proc 2010;31:49-59.
304. Brozek JL, Kraft M, Krishnan JA, Cloutier MM, Lazarus SC, Li JT, et al. Long-Acting s2-Agonist step-off in patients with controlled asthma. Arch Intern Med 2012;172:1365-75.
305. Masoli M, Weatherall M, Holt S, Beasley R. Budesonide once versus twice-daily administration: Meta-Analysis. Respirology 2004;9:528-34.
306. Rank MA, Hagan JB, Park MA, Podjasek JC, Samant SA, Volcheck GW, et al. The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: A systematic review and meta-Analysis of randomized controlled trials. J Allergy Clin Immunol 2013;131:724-9.
307. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al.; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: Asthma control and exacerbations: Standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180:59-99.
308. Rebuck AS, Pengelly LD. Development of pulsus paradoxus in the presence of airways obstruction. N Engl J Med 1973;288:66-9.
309. McFadden Jr. ER., Kiser R, DeGroot WJ. Acute bronchial asthma. Relations between clinical and physiologic manifestations. N Engl J Med 1973;288:221-5.
310. Brenner BE, Abraham E, Simon RR. Position and diaphoresis in acute asthma. Am J Med 1983;74:1005-9.
311. McFadden Jr. ER. Acute severe asthma. Am J Respir Crit Care Med 2003;168:740-59.
312. Tai E, Read J. Blood-gas tensions in bronchial asthma. Lancet 1967;1:644-6.
313. Weng TR, Langer HM, Featherby EA, Levison H. Arterial blood gas tensions and acid-base balance in symptomatic and asymptomatic asthma in childhood. Am Rev Respir Dis 1970;101:274-82.
314. Miyamoto T, Mizuno K, Furuya K. Arterial blood gases in bronchial asthma. J Allergy 1970;45:248-54.
315. Rees HA, Millar JS, Donald KW. A study of the clinical course and arterial blood gas tensions of patients in status asthmaticus. Q J Med 1968;37:541-61.
316. Carruthers DM, Harrison BD. Arterial blood gas analysis or oxygen saturation in the assessment of acute asthma?. Thorax 1995;50:186-8.
317. Jones J, Heiselman D, Cannon L, Gradisek R. Continuous emergency department monitoring of arterial saturation in adult patients with respiratory distress. Ann Emerg Med 1988;17:463-8.
318. Geelhoed GC, Landau LI, Le Souef PN. Evaluation of SaO2 as a predictor of outcome in 280 children presenting with acute asthma. Ann Emerg Med 1994;23:1236-41.
319. McFadden Jr. ER., Elsanadi N, Dixon L, Takacs M, Deal EC, Boyd KK, et al. Protocol therapy for acute asthma: Therapeutic benefits and cost savings. Am J Med 1995;99:651-61.
320. Strauss L, Hejal R, Galan G, Dixon L, McFadden Jr. ER. Observations on the effects of aerosolized albuterol in acute asthma. Am J Respir Crit Care Med 1997;155:454-8.
321. Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Bauer CA, OByrne PM, et al. Exacerbations of asthma: A descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med 1999;160:594-9.
322. Rodrigo GJ, Rodriquez Verde M, Peregalli V, Rodrigo C. Effects of short-Term 28% and 100% oxygen on PaCO2 and peak expiratory flow rate in acute asthma: A randomized trial. Chest 2003;124:1312-7.
323. Perrin K, Wijesinghe M, Healy B, Wadsworth K, Bowditch R, Bibby S, et al. Randomised controlled trial of high concentration versus titrated oxygen therapy in severe exacerbations of asthma. Thorax 2011;66:937-41.
324. Rodriguez-Roisin R. Acute severe asthma: Pathophysiology and pathobiology of gas exchange abnormalities. Eur Respir J 1997;10:1359-71.
325. Rodrigo GJ, Rodrigo C, Hall JB. Acute asthma in adults: A review. Chest 2004;125:1081-102.
326. Emerman CL, Cydulka RK, McFadden ER. Comparison of 2.5 vs 7.5 mg of inhaled albuterol in the treatment of acute asthma. Chest 1999;115:92-6.
327. Rodrigo GJ, Nannini LJ. Comparison between nebulized adrenaline and beta2 agonists for the treatment of acute asthma. A meta-Analysis of randomized trials. Am J Emerg Med 2006;24:217-22.
328. Morley J. Anomalous effects of albuterol and other sympathomimetics in the guinea pig. Clin Rev Allergy Immunol 1996;14:65-89.
329. Page CP, Morley J. Contrasting properties of albuterol stereoisomers. J Allergy Clin Immunol 1999;104:S31-41.
330. Handley DA, Anderson AJ, Koester J, Snider ME. New millennium bronchodilators for asthma: Single-isomer beta agonists. Curr Opin Pulm Med 2000;6:43-9.
331. Templeton AG, Chapman ID, Chilvers ER, Morley J, Handley DA. Effects of S-salbutamol on human isolated bronchus. Pulm Pharmacol Ther 1998;11:1-6.
332. Nowak R, Emerman C, Hanrahan JP, Parsey MV, Hanania NA, Claus R, et al.; XOPENEX Acute Severe Asthma Study Group. A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. Am J Emerg Med 2006; 24: 259-67.
333. Jat KR, Khairwa A. Levalbuterol versus albuterol for acute asthma: A systematic review and meta-Analysis. Pulm Pharmacol Ther 2013;26:239-48.
334. Rodrigo GJ, Neffen H, Colodenco FD, Castro-Rodriguez JA. Formoterol for acute asthma in the emergency department: A systematic review with meta-Analysis. Ann Allergy Asthma Immunol 2010;104:247-52.
335. Adoun M, Frat JP, Dore P, Rouffineau J, Godet C, Robert R. Comparison of nebulized epinephrine and terbutaline in patients with acute severe asthma: A controlled trial. J Crit Care 2004;19:99-102.
336. Shrestha M, Bidadi K, Gourlay S, Hayes J. Continuous vs intermittent albuterol, at high and low doses, in the treatment of severe acute asthma in adults. Chest 1996;110:42-7.
337. Travers AH, Rowe BH, Barker S, Jones A, Camargo Jr. CA. The effectiveness of IV beta-Agonists in treating patients with acute asthma in the emergency department: A meta-Analysis. Chest 2002;122:1200-7.
338. Nair P, Milan SJ, Rowe BH. Addition of intravenous aminophylline to inhaled beta (2)-Agonists in adults with acute asthma. Cochrane Database Syst Rev 2012;12:CD002742.
339. Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-Agonist treatment of acute asthma. Cochrane Database Syst Rev 2013;9:CD000052.
340. Camargo Jr. CA., Spooner CH, Rowe BH. Continuous versus intermittent beta-Agonists in the treatment of acute asthma. Cochrane Database Syst Rev 2003;CD001115.
341. Fryer AD, Jacoby DB. Effect of inflammatory cell mediators on M2 muscarinic receptors in the lungs. Life Sci 1993;52:529-36.
342. Leahy BC, Gomm SA, Allen SC. Comparison of nebulized salbutamol with nebulized ipratropium bromide in acute asthma. Br J Dis Chest 1983;77:159-63.
343. Ward MJ, Fentem PH, Smith WH, Davies D. Ipratropium bromide in acute asthma. Br Med J (Clin Res Ed) 1981;282:598-600.
344. Summers QA, Tarala RA. Nebulized ipratropium in the treatment of acute asthma. Chest 1990;97:425-9.
345. Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children and adults with acute asthma: A systematic review with meta-Analysis. Thorax 2005;60:740-6.
346. Salo D, Tuel M, Lavery RF, Reischel U, Lebowitz J, Moore T. A randomized, clinical trial comparing the efficacy of continuous nebulized albuterol (15 mg) versus continuous nebulized albuterol (15 mg) plus ipratropium bromide (2 mg) for the treatment of acute asthma. J Emerg Med 2006;31:371-6.
347. Aggarwal P, Singh O, Wali JP, Handa R, Dwivedi SN, Biswas A, et al. Efficacy of nebulized ipratropium in acute bronchial asthma. J Indian Acad Clin Med 2002;3:353-9.
348. Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW. Corticosteroids for preventing relapse following acute exacerbations of asthma. Cochrane Database Syst Rev 2007;CD000195.
349. Sherman MS, Verceles AC, Lang D. Systemic steroids for the treatment of acute asthma: Where do we stand?. Clin Pulm Med 2006;13:315-20.
350. Rowe BH, Spooner C, Ducharme FM, Bretzlaff JA, Bota GW. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev 2001;CD002178.
351. Manser R, Reid D, Abramson M. Corticosteroids for acute severe asthma in hospitalised patients. Cochrane Database Syst Rev 2001;CD001740.
352. Hasegawa T, Ishihara K, Takakura S, Fujii H, Nishimura T, Okazaki M, et al. Duration of systemic corticosteroids in the treatment of asthma exacerbation; a randomized study. Intern Med 2000;39:794-7.
353. Jones AM, Munavvar M, Vail A, Aldridge RE, Hopkinson L, Rayner C, et al. Prospective, placebo-controlled trial of 5 vs 10 days of oral prednisolone in acute adult asthma. Respir Med 2002; 96: 950-4.
354. ODriscoll BR, Kalra S, Wilson M, Pickering CA, Carroll KB, Woodcock AA. Double-blind trial of steroid tapering in acute asthma. Lancet 1993;341:324-7.
355. Lederle FA, Pluhar RE, Joseph AM, Niewoehner DE. Tapering of corticosteroid therapy following exacerbation of asthma. A randomized, double-blind, placebo-controlled trial. Arch Intern Med 1987;147:2201-3.
356. Edmonds ML, Milan SJ, Camargo Jr. CA., Pollack CV, Rowe BH. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Rev 2012;12:CD002308.
357. Rodrigo GJ. Comparison of inhaled fluticasone with intravenous hydrocortisone in the treatment of adult acute asthma. Am J Respir Crit Care Med 2005;171:1231-6.
358. Edmonds ML, Milan SJ, Brenner BE, Camargo Jr. CA., Rowe BH. Inhaled steroids for acute asthma following emergency department discharge. Cochrane Database Syst Rev 2012;12:CD002316.
359. Rowe BH, Camargo Jr. CA. The role of magnesium sulfate in the acute and chronic management of asthma. Curr Opin Pulm Med 2008;14:70-6.
360. Silverman RA, Osborn H, Runge J, Gallagher EJ, Chiang W, Feldman J, et al.; AcuteAsthma/Magnesium Study Group. IV magnesium sulfate in the treatment of acute severe asthma: A multicenter randomized controlled trial. Chest 2002;122:489-97.
361. Rowe BH, Bretzlaff JA, Bourdon C, Bota GW, Camargo Jr. CA. Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database Syst Rev 2000;CD001490.
362. Goodacre S, Cohen J, Bradburn M, Gray A, Benger J, Coats T, 3Mg Research Team. Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): A double-blind, randomised controlled trial. Lancet Respir Med 2013;1:293-300.
363. Powell C, Dwan K, Milan SJ, Beasley R, Hughes R, Knopp-Sihota JA, et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database Syst Rev 2012;12:CD003898.
364. Green SA, Malice MP, Tanaka W, Tozzi CA, Reiss TF. Increase in urinary leukotriene LTE4 levels in acute asthma: Correlation with airflow limitation. Thorax 2004;59:100-4.
365. Cylly A, Kara A, Ozdemir T, Oʇus C, Gulkesen KH. Effects of oral montelukast on airway function in acute asthma. Respir Med 2003;97:533-6.
366. Ramsay CF, Pearson D, Mildenhall S, Wilson AM. Oral montelukast in acute asthma exacerbations: A randomised, double-blind, placebo-controlled trial. Thorax 2011;66:7-11.
367. Camargo Jr. CA., Smithline HA, Malice MP, Green SA, Reiss TF. A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med 2003;167:528-33.
368. Camargo Jr. CA., Gurner DM, Smithline HA, Chapela R, Fabbri LM, Green SA, et al. A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma. J Allergy Clin Immunol 2010;125:374-80.
369. Adachi M, Taniguchi H, Tohda Y, Sano Y, Ishine T, Smugar SS, et al. The efficacy and tolerability of intravenous montelukast in acute asthma exacerbations in Japanese patients. J Asthma 2012;49:649-56.
370. Graham V, Lasserson T, Rowe BH. Antibiotics for acute asthma. Cochrane Database Syst Rev 2001;CD002741.
371. Gupta D, Agarwal R, Aggarwal AN, Singh N, Mishra N, Khilnani GC, et al.; Pneumonia Guidelines Working Group. Guidelines for diagnosis and management of community-And hospital-Acquired pneumonia in adults: Joint ICS/NCCP (I) recommendations. Lung India 2012;29(Suppl 2):S27-62.
372. Gupta D, Nath A, Agarwal R, Behera D. A prospective randomized controlled trial on the efficacy of noninvasive ventilation in severe acute asthma. Respir Care 2010;55:536-43.
373. Lim WJ, Mohammed Akram R, Carson KV, Mysore S, Labiszewski NA, Wedzicha JA, et al. Non-invasive positive pressure ventilation for treatment of respiratory failure due to severe acute exacerbations of asthma. Cochrane Database Syst Rev 2012;12:CD004360.
374. Manthous CA, Morgan S, Pohlman A. Heliox in the treatment of airflow obstruction: A critical review of the literature. Respir Care 1997;42:1034-42.
375. Rodrigo GJ, Rodrigo C, Pollack CV, Rowe B. Use of helium-oxygen mixtures in the treatment of acute asthma: A systematic review. Chest 2003;123:891-6.
376. Rodrigo GJ, Castro-Rodriguez JA. Heliox-driven s2-Agonists nebulization for children and adults with acute asthma: A systematic review with meta-Analysis. Ann Allergy Asthma Immunol 2014;112:29-34.
377. Celano M, Geller RJ, Phillips KM, Ziman R. Treatment adherence among low-income children with asthma. J Pediatr Psychol 1998;23:345-9.
378. Cerveri I, Locatelli F, Zoia MC, Corsico A, Accordini S, de Marco R. International variations in asthma treatment compliance: The results of the European Community Respiratory Health Survey (ECRHS). Eur Respir J 1999;14:288-94.
379. Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, et al.; Gruppo Educazionale Associazione Italiana Pneumologi Ospedalieri. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011;105:930-8.
380. Tano BD. All that wheezes is not asthma: Misclassification, comorbidities and treatment outcomes in acute asthma exacerbations. J Allergy Clin Immunol 2008;121 Suppl 1:S162.
381. Koul PA, Khan UH, Shah TH, Dar AM. All that wheezes is not asthma. BMJ Case Rep 2014;2014. pii: bcr2013202369.
382. McSharry DG, McElwaine P, Segadal L, McNicholas WT. All that wheezes is not asthma. Lancet 2007;370:800.
383. Koul PA, Wahid A, Bhat TA, Hussain T. Whistle in the bronchus. Ann Thorac Med 2007;2:124-5.
384. De S, De S. Post intubation tracheal stenosis. Indian J Crit Care Med 2008;12:194-7.
385. Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma: Systematic review and meta-Analysis. Int J Tuberc Lung Dis 2009;13:936-44.
386. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002;57:226-30.
387. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003;168:1308-11.
388. Guven SF, Dursun AB, Ciftci B, Erkekol FO, Kurt OK. The prevalence of obstructive sleep apnea in patients with difficult-To-Treat asthma. Asian Pac J Allergy Immunol 2014;32:153-9.
389. Chan WW, Chiou E, Obstein KL, Tignor AS, Whitlock TL. The efficacy of proton pump inhibitors for the treatment of asthma in adults: A meta-Analysis. Arch Intern Med 2011;171:620-9.
390. Eneli IU, Skybo T, Camargo Jr. CA. Weight loss and asthma: A systematic review. Thorax 2008;63:671-6.
391. Lohia S, Schlosser RJ, Soler ZM. Impact of intranasal corticosteroids on asthma outcomes in allergic rhinitis: A meta-Analysis. Allergy 2013;68:569-79.
392. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: A systematic review. Chest 2011;139:28-35.
393. Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014;1:CD003559.
394. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302-8.
395. Kuprys-Lipinska I, Kuna P. Loss of asthma control after cessation of omalizumab treatment: Real life data. Postepy Dermatol Alergol 2014;31:1-5.
396. Castro M, Rubin AS, Laviolette M, Fiterman J, De Andrade Lima M, Shah PL, et al.; AIR2 Trial Study Group. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: A multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010;181:116-24.
397. Cox G, Thomson NC, Rubin AS, Niven RM, Corris PA, Siersted HC, et al.; AIR Trial Study Group. Asthma control during the year after bronchial thermoplasty. N Engl J Med 2007;356:1327-37.
398. Pavord ID, Cox G, Thomson NC, Rubin AS, Corris PA, Niven RM, et al.; RISA Trial Study Group. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med 2007;176:1185-91.
399. Iyer VN, Lim KG. Bronchial thermoplasty: Reappraising the evidence (or lack thereof). Chest 2014;146:17-21.
400. Torrego A, Sola I, Munoz AM, Roque I Figlus M, Yepes-Nunez JJ, Alonso-Coello P, et al. Bronchial thermoplasty for moderate or severe persistent asthma in adults. Cochrane Database Syst Rev 2014;3:CD009910.
401. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010;CD001186.
402. Long-Term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med 2000;343:1054-63.
403. Kemp JP, Cook DA, Incaudo GA, Corren J, Kalberg C, Emmett A, et al. Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids. Salmeterol Quality of Life Study Group. J Allergy Clin Immunol 1998;101:188-95.
404. Calderon MA, Cox L, Casale TB, Moingeon P, Demoly P. Multiple-Allergen and single-Allergen immunotherapy strategies in polysensitized patients: Looking at the published evidence. J Allergy Clin Immunol 2012;129:929-34.
405. Srivastava D, Singh BP, Arora N, Gaur SN. Clinico-immunologic study on immunotherapy with mixed and single insect allergens. J Clin Immunol 2009;29:665-73.
406. Calamita Z, Saconato H, Pelá AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: Systematic review of randomized-clinical trials using the cochrane collaboration method. Allergy 2006;61:1162-72.
407. Amar SM, Harbeck RJ, Sills M, Silveira LJ, OBrien H, Nelson HS. Response to sublingual immunotherapy with grass pollen extract: Monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol 2009;124:150-6.e1-5.
408. Borchers AT, Keen CL, Gershwin ME. Fatalities following allergen immunotherapy. Clin Rev Allergy Immunol 2004;27:147-58.
409. Nettis E, Giordano D, Ferrannini A, Tursi A. Systemic reactions to allergen immunotherapy: A review of the literature. Immunopharmacol Immunotoxicol 2003;25:1-11.
410. Gibson PG, Powell H, Coughlan J, Wilson AJ, Hensley MJ, Abramson M, et al. Limited (information only) patient education programs for adults with asthma. Cochrane Database Syst Rev 2002;CD001005.
411. Gibson PG, Powell H, Coughlan J, Wilson AJ, Abramson M, Haywood P, et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev 2003;CD001117.
412. Bindroo SK, Kumar R, Gaur SN. Effect of home-based pulmonary rehabilitation programme on disability in patients with persistent bronchial asthma. Indian J Allergy Asthma Immunol 2002;18:63-71.
413. Carson KV, Chandratilleke MG, Picot J, Brinn MP, Esterman AJ, Smith BJ. Physical training for asthma. Cochrane Database Syst Rev 2013;9:CD001116.
414. Cates CJ, Rowe BH. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev 2013;2:CD000364.
415. Sheikh A, Alves B, Dhami S. Pneumococcal vaccine for asthma. Cochrane Database Syst Rev 2002;CD002165.
416. Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): A multicentre randomised double-blind placebo-controlled trial. Thorax 2013;68:322-9.
417. Kwon HL, Belanger K, Bracken MB. Asthma prevalence among pregnant and childbearing-Aged women in the United States: Estimates from national health surveys. Ann Epidemiol 2003;13:317-24.
418. Schatz M, Harden K, Forsythe A, Chilingar L, Hoffman C, Sperling W, et al. The course of asthma during pregnancy, post partum, and with successive pregnancies: A prospective analysis. J Allergy Clin Immunol 1988;81:509-17.
419. Demissie K, Breckenridge MB, Rhoads GG. Infant and maternal outcomes in the pregnancies of asthmatic women. Am J Respir Crit Care Med 1998;158:1091-5.
420. Kallen B, Rydhstroem H, Aberg A. Asthma during pregnancy-A population based study. Eur J Epidemiol 2000;16:167-71.
421. Schatz M, Zeiger RS, Hoffman CP, Harden K, Forsythe A, Chilingar L, et al. Perinatal outcomes in the pregnancies of asthmatic women: A prospective controlled analysis. Am J Respir Crit Care Med 1995;151:1170-4.
422. Murphy VE, Clifton VL, Gibson PG. Asthma exacerbations during pregnancy: Incidence and association with adverse pregnancy outcomes. Thorax 2006;61:169-76.
423. Tata LJ, Lewis SA, McKeever TM, Smith CJ, Doyle P, Smeeth L, et al. Effect of maternal asthma, exacerbations and asthma medication use on congenital malformations in offspring: A UK population-based study. Thorax 2008;63:981-7.
424. Schatz M, Zeiger RS, Harden K, Hoffman CC, Chilingar L, Petitti D. The safety of asthma and allergy medications during pregnancy. J Allergy Clin Immunol 1997;100:301-6.
425. Bakhireva LN, Jones KL, Schatz M, Klonoff-Cohen HS, Johnson D, Slymen DJ, et al.; Organization of Teratology Information Specialists Collaborative Research Group. Safety of leukotriene receptor antagonists in pregnancy. J Allergy Clin Immunol 2007;119:618-25.
426. Sarkar M, Koren G, Kalra S, Ying A, Smorlesi C, De Santis M, et al. Montelukast use during pregnancy: A multicentre, prospective, comparative study of infant outcomes. Eur J Clin Pharmacol 2009;65:1259-64.
427. Bracken MB, Triche EW, Belanger K, Saftlas A, Beckett WS, Leaderer BP. Asthma symptoms, severity, and drug therapy: A prospective study of effects on 2205 pregnancies. Obstet Gynecol 2003;102:739-52.
428. Working Group Report on Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment. National Asthma Education and Prevention Program, National Heart, Lung, and Blood Institute. Available form: https://www.nhlbi.nih.gov/files/docs/resources/ lung/astpreg-full.pdf. [Last accessed on 2004 Mar 05].
429. Perlow JH, Montgomery D, Morgan MA, Towers CV, Porto M. Severity of asthma and perinatal outcome. Am J Obstet Gynecol 1992;167:963-7.
430. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776-89.
431. Dryden DM, Spooner CH, Stickland MK, Vandermeer B, Tjosvold L, Bialy L, et al. Exercise-induced bronchoconstriction and asthma. Evid Rep Technol Assess (Full Rep) 2010;1-154, v-vi.
432. Godfrey S, Springer C, Bar-Yishay E, Avital A. Cut-off points defining normal and asthmatic bronchial reactivity to exercise and inhalation challenges in children and young adults. Eur Respir J 1999;14:659-68.
433. Bonini M, Di Mambro C, Calderon MA, Compalati E, Schunemann H, Durham S, et al. Beta2-Agonists for exercise-induced asthma. Cochrane Database Syst Rev 2013;10:CD003564.
434. Parsons JP, Hallstrand TS, Mastronarde JG, Kaminsky DA, Rundell KW, Hull JH, et al.; American Thoracic Society Subcommittee on Exercise-induced Bronchoconstriction. An official American Thoracic Society clinical practice guideline: Exercise-induced bronchoconstriction. Am J Respir Crit Care Med 2013;187:1016-27.
435. Babu KS, Salvi SS. Aspirin and asthma. Chest 2000;118:1470-6.
436. Stevenson DD. Oral challenges to detect aspirin and sulfite sensitivity in asthma. N Engl Reg Allergy Proc 1988;9:135-42.
437. Simon RA. Oral challenges to detect aspirin and sulfite sensitivity in asthma. Allerg Immunol (Paris) 1994;26:216-8.
438. Bush RK, Zoratti E, Taylor SL. Diagnosis of sulfite and aspirin sensitivity. Clin Rev Allergy 1990;8:159-78.
439. Nizankowska E, Bestynska-Krypel A, Cmiel A, Szczeklik A. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J 2000;15:863-9.
440. Milewski M, Mastalerz L, Nizankowska E, Szczeklik A. Nasal provocation test with lysine-Aspirin for diagnosis of aspirin-sensitive asthma. J Allergy Clin Immunol 1998;101:581-6.
441. Dahlen B, Szczeklik A, Murray JJ, Celecoxib in Aspirin-Intolerant Asthma Study Group. Celecoxib in patients with asthma and aspirin intolerance. The Celecoxib in Aspirin-Intolerant Asthma Study Group. N Engl J Med 2001;344:142.
442. El Miedany Y, Youssef S, Ahmed I, El Gaafary M. Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2006;97:105-9.
443. Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001;108:47-51.
444. Woessner KM, Simon RA, Stevenson DD. Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2004;93:339-44.
445. Settipane RA, Schrank PJ, Simon RA, Mathison DA, Christiansen SC, Stevenson DD. Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects. J Allergy Clin Immunol 1995;96:480-5.
446. Kowalski ML. Management of aspirin-sensitive rhinosinusitis-Asthma syndrome: What role for aspirin desensitization?. Allergy Proc 1992;13:175-84.
447. Stevenson DD, Hankammer MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-Asthma: Long-Term outcomes. J Allergy Clin Immunol 1996;98:751-8.
448. Dahlen SE, Malmström K, Nizankowska E, Dahlen B, Kuna P, Kowalski M, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: A randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:9-14.
449. de Groene GJ, Pal TM, Beach J, Tarlo SM, Spreeuwers D, Frings-Dresen MH, et al. Workplace interventions for treatment of occupational asthma. Cochrane Database Syst Rev 2011;CD006308.
450. Denning DW, Pleuvry A, Cole DC. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol 2013;51:361-70.
451. Agarwal R, Chakrabarti A, Shah A, Gupta D, Meis JF, Guleria R, et al.; ABPA complicating asthma ISHAM working group. Allergic bronchopulmonary aspergillosis: Review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 2013;43:850-73.
452. Patterson R, Greenberger PA, Halwig JM, Liotta JL, Roberts M. Allergic bronchopulmonary aspergillosis. Natural history and classification of early disease by serologic and roentgenographic studies. Arch Intern Med 1986;146:916-8.
453. Agarwal R, Gupta D, Aggarwal AN, Behera D, Jindal SK. Allergic bronchopulmonary aspergillosis: Lessons from 126 patients attending a chest clinic in north India. Chest 2006;130:442-8.